Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

Several other equities research analysts have also recently commented on VRNA. Stifel Nicolaus started coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued a “buy” rating and a $22.00 price objective on the stock. SunTrust Banks, Inc. started coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued a “buy” rating and a $26.00 price objective on the stock. Wedbush started coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued an “outperform” rating and a $25.00 price objective on the stock. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Verona Pharma PLC American Depositary Share presently has a consensus rating of “Buy” and an average price target of $22.60.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) traded up 2.2072% during mid-day trading on Tuesday, hitting $12.2342. The company had a trading volume of 4,938 shares. The firm’s 50-day moving average price is $14.21 and its 200 day moving average price is $14.01. Verona Pharma PLC American Depositary Share has a one year low of $11.03 and a one year high of $17.50. The company’s market capitalization is $78.54 million.

TRADEMARK VIOLATION WARNING: “Verona Pharma PLC American Depositary Share (VRNA) Stock Rating Lowered by Zacks Investment Research” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/verona-pharma-plc-american-depositary-share-vrna-stock-rating-lowered-by-zacks-investment-research.html.

An institutional investor recently bought a new position in Verona Pharma PLC American Depositary Share stock. Vivo Capital LLC purchased a new stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the second quarter, according to its most recent filing with the SEC. The institutional investor purchased 704,225 shares of the company’s stock, valued at approximately $8,208,000. Verona Pharma PLC American Depositary Share comprises about 2.1% of Vivo Capital LLC’s investment portfolio, making the stock its 11th largest position. Vivo Capital LLC owned about 10.97% of Verona Pharma PLC American Depositary Share as of its most recent SEC filing. 5.09% of the stock is owned by institutional investors and hedge funds.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.